$2.08
-0.12-5.45%
At Close: -
$2.07
-0.01-0.65%
After Hours: 6:32 PM EDT
15 minutes delayed
Comments
Loading...
Prelude Therapeutics (PRLD) Forecast
NewsEarningsGuidanceDividendsAnalyst RatingsInsider TradesShort InterestPrelude Therapeutics (NASDAQ:PRLD) Stock Quotes, Forecast and News Summary
Prelude Therapeutics Stock (NASDAQ: PRLD) stock price, news, charts, stock research, profile.
Compare
EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
EPS worse than industry
FAQ
How do I buy Prelude Therapeutics (PRLD) stock?
You can purchase shares of Prelude Therapeutics (NASDAQ:PRLD) through any online brokerage.
Who are Prelude Therapeutics (PRLD) competitors?
Other companies in Prelude Therapeutics’s space includes: Outlook Therapeutics (NASDAQ:OTLK), Skye Bioscience (NASDAQ:SKYE), Anixa Biosciences (NASDAQ:ANIX), Citius Oncology (NASDAQ:CTOR) and Adicet Bio (NASDAQ:ACET).
What is the forecast, or price target, for Prelude Therapeutics (PRLD) stock?
Prelude Therapeutics has a consensus price target of $6.00.
What is the current price for Prelude Therapeutics (PRLD)?
The stock price for Prelude Therapeutics (NASDAQ: PRLD) is $2.0665 last updated September 25, 2024 at 6:32 PM EDT.
Does Prelude Therapeutics (PRLD) pay a dividend?
There are no upcoming dividends for Prelude Therapeutics.
When is Prelude Therapeutics (NASDAQ:PRLD) reporting earnings?
Prelude Therapeutics’s Q3 earnings are confirmed for Wednesday, October 30, 2024.
Is Prelude Therapeutics (PRLD) going to split?
There is no upcoming split for Prelude Therapeutics.
What sector and industry does Prelude Therapeutics (PRLD) operate in?
Prelude Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.